Skip to Content
Merck
All Photos(1)

Documents

SAB4301393

Sigma-Aldrich

Anti-phospho-FGFR4 (pTyr642) antibody produced in rabbit

affinity isolated antibody

Synonym(s):

CD_antigen CD334, EC 2.7.10.1, FGFR-4, Fibroblast growth factor receptor 4, JTK2, TKF

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

90 kDa

species reactivity

human

concentration

1.0 mg/mL

technique(s)

western blot: 1:500-1:1000 (Cell Lysate)

isotype

IgG

accession no.

NP_002002.3.

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

phosphorylation (pTyr642)

Gene Information

human ... FGFR4(2264)

General description

Fibroblast growth factor receptor 4 (FGFR4) protein is a tyrosine kinase (TK) receptor comprising an extracellular domain, a transmembrane domain, and an intracellular domain. FGFR4 is expressed in the adrenal cortex, bile duct, cervix, cornea, heart, hepatocyte, intestine, kidney, liver, lung, lymph node, mammary gland, muscle, ovary, pituitary gland, renal tubular epithelium, retina, skin, spleen, stomach, ureter, urothelium, and uterus. FGFR4 gene is located on human chromosome 5q35.2.

Specificity

The antibody detects endogenous levels of FGFR4 only when phosphorylated at tyrosine 642.

Immunogen

Peptide sequence around phosphorylation site of tyrosine 642(I-D-Y(p)-Y-K) derived from Human FGFR4 .

Biochem/physiol Actions

Fibroblast growth factor receptor 4 (FGFR4) protein possesses tyrosine-protein kinase activity and serves as a cell-surface receptor for fibroblast growth factors. It regulates cell proliferation, differentiation, and migration. FGFR4 also participates in survival during embryonic development. It helps with tissue homeostasis, tissue repair, angiogenesis, and inflammation in adults. FGFR4 is expressed at a high level in various cancer types. It plays a key role in tumor subtype differentiation in luminal breast cancer and metastatic disease. Oncogenic mutations of the FGFR4 gene are associated with rhabdomyosarcoma (RMS) and primary gastric cancer.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

FGFR4 (fibroblast growth factor receptor 4)
Pelaez-Garcia A, et al.
Atlas of Genetics and Cytogenetics in Oncology and Haematology (2012)
Susana Garcia-Recio et al.
The Journal of clinical investigation, 130(9), 4871-4887 (2020-06-24)
Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise to HER2-enriched (HER2E) subtype metastases, but remain clinically HER2 negative
Takashi Futami et al.
Scientific reports, 9(1), 14627-14627 (2019-10-12)
Gastric cancer remains one of the leading causes of cancer death worldwide. Despite intensive investigations of treatments over the past three decades, the poor prognosis of patients with unresectable advanced or recurrent gastric cancer has not significantly changed, and improved

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service